Los Angeles Capital Management
DAWN

Los Angeles Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Los Angeles Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,314
Closed -$706K – 2446
2025
Q4 		$706K Buy
100,314
+1,425
+1% +$11.9K ﹤0.01% 764
2025
Q3 		$697K Buy
98,889
+16,632
+20% +$114K ﹤0.01% 816
2025
Q2 		$535K Buy
82,257
+27,335
+50% +$188K ﹤0.01% 845
2025
Q1 		$436K Buy
+54,922
New +$592K ﹤0.01% 783

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Los Angeles Capital Management's DAWN Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 100,314 shares — an estimated $706K sold.

Los Angeles Capital Management first reported a position in DAWN in Q1 2025 and held it in 4 quarters. The position peaked at $706K in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 100,314 Day One Biopharmaceuticals shares in Q1 2026, an estimated $706K.
  • Los Angeles Capital Management first reported a position in Day One Biopharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Los Angeles Capital Management's Day One Biopharmaceuticals position peaked at $706K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.